Medical guidelines and recommendations take center stage at AUA2023
Optimizing patient outcomes with scientific evidence, including Dr. Neal D. Shore’s practice-changing data in prostate cancer.
For 118 years, the AUA Annual Meeting has been providing unparalleled access to groundbreaking research, new guidelines and the latest advances in urological medicine. AUA2023 carried on that tradition, setting the highest standards for innovative, evidence-based quality education for urologists and urological health care professionals worldwide.
Neal D. Shore, MD
One of the most exciting announcements at the Annual Meeting came from Neal D. Shore, MD, medical director of the Carolina Urologic Research Center/GenesisCare U.S., who shared the EMBARK study pointing to a potential new standard of care for high-risk biochemically recurrent prostate cancer (BCR) during Saturday’s Plenary.
The three-arm EMBARK study of leuprolide acetate (LA) plus enzalutamide (combo) vs. enzalutamide monotherapy (enza) vs. LA + placebo in patients with BCR showed statistically significant and clinically significant improvement in metastasis-free survival (MFS), risk of prostate-specific antigen (PSA) progression and time to first use of a new neoplastic agent.
A number of sessions at AUA2023 presented updated guidelines, new guidelines or emphasized the importance of following guidelines in everyday practice.
In conjunction with the 2023 release of “Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline,” Surena F. Matin, MD, the Monteleone Family Foundation Distinguished Professor in the department of urology at MD Anderson Cancer Center in Houston, led a distinguished panel of urologists whose clinical practice focuses on the treatment of urothelial carcinoma (or cancers) in Friday’s session, “Management of Upper Tract Urothelial Carcinoma.” The discussion featured select topics on managing urothelial carcinoma (or cancers), which coincides with the release of the new guidelines.
Tomas L. Griebling, MD, MPH, FACS, the John P. Wolf 33 Masonic distinguished professor of urology at the University of Kansas School of Medicine, and Camille P. Vaughan, MD, MS, division director of geriatrics and gerontology at the Emory University School of Medicine, weighed in on recurrent urinary tract infections and offered their treatment recommendations in accordance with AUA Guideline statements during “Second Opinion Cases: The Growing Problem of Antibiotic Resistance for Urinary Tract Infection in Geriatrics” on Sunday.
For the most up-to-date resources on guidelines in urology, look to the AUA.